A Study of Ixekizumab in Participants With Active Psoriatic Arthritis

Inclusion Criteria:

- Presents with established diagnosis of active psoriatic arthritis for at least 6
months, and currently meets Classification for Psoriatic Arthritis (CASPAR) criteria

- Active psoriatic arthritis (PsA) defined as the presence of at least 3 tender and at
least 3 swollen joints

- Presence of active psoriatic skin lesion or a personal history of plaque psoriasis
(Ps)

- Men must agree to use a reliable method of birth control or remain abstinent during
the study

- Women must agree to use reliable birth control or remain abstinent during the study
and for at least 12 weeks after stopping treatment

Exclusion Criteria:

- Current or prior use of biologic agents for treatment of Ps or PsA

- Inadequate response to greater than or equal to 4 conventional disease-modifying
antirheumatic drugs (DMARDs)

- Current use of more than one conventional DMARD

- Evidence of active inflammatory arthritic syndromes or spondyloarthropathies other
than PsA

- Have participated in any study with interleukin 17 (IL-17) antagonists, including
ixekizumab

- Serious disorder or illness other than psoriatic arthritis

- Serious infection within the last 3 months

- Breastfeeding or nursing (lactating) women